Chronic
Retrieval

AVEIR™ VR Leadless Pacemaker’s
helical fixation is designed for
chronic retrieval, expanding
therapeutic options.1,2*
Long
Lasting

Battery is projected to offer up to
twice the longevity of current VR
leadless pacemakers based on ISO
standard settings.1,3**
Mapping Prior to Fixation

AVEIR™ VR Leadless Pacemaker mapping capability is designed to help reduce the number of
repositioning attempts.1,4
Download the Physician Brochure to see all AVEIR VR Leadless Pacemaker has to offer
Life-Changing Innovation
Dual-chamber system expandability
The software for AVEIR VR Leadless Pacemaker was designed for expandability to a dual chamber system to be introduced to the AVEIR VR system via software updates in the future, upon regulatory approval.1***

AVEIR VR LP is 1.5T and 3T MR Conditional
AVEIR VR LP is MR Conditional for full body scans using a 1.5T or 3T field strength MRI scanner.****



View the Clinical Study
References
* Limited data is available for Aveir Leadless Pacemaker. The Aveir Leadless Pacemaker’s predicate device has chronic retrieval success rate >80% with helix fixation through 7 years regardless of implant duration
** ISO standard settings: VVIR, 60bpm, 2.5V @0.4 ms, 600 Ω, 100% pacing
***CAUTION: Dual Chamber configuration is currently investigational and is limited to investigational use only in accordance with Canadian Law. Contact your local sales representative for the regulatory status of the device(s) in Canada
**** Stability of pacing capture thresholds is required prior to MRI scan. For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI Ready resources at cardiovascular.abbott/mriready
- Aveir™ VR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600175956
- Reddy VY, et al. Chronic Retrievability with a Leadless Pacemaker: A Worldwide Nanostim Experience out of 7y. Presented at: HRS 2021; Jul 28-31, 2021; Boston, MA.
- Micra‡ VR IFU M991010A001 REV. B
- Reddy, VY et al. Primary Results on Safety and Efficacy from the LEADLESS II-Phase 2 Worldwide Clinical Trial, JACC: Clinical Electrophysiology, 2021, ISSN 2405-500X, https://doi.org/10.1016/j.jacep.2021.11.002.
MAT-2210336 v1.0 | Item approved for Canada use only.
Disclaimer
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0